BioPharma Clinical Trials

GenFleet Therapeutics Collaborates with BeiGene for Advanced Lymphoma Trial

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced it has entered into ...

 March 29, 2024 | News

Lunit Reveals Positive Study Results for Head and Neck Cancer Immunotherapy

Lunit, a global leader in AI-driven cancer diagnostics and therapy solutions, is thrilled to share the publication of a groundbreaking study in the prestig...

 March 27, 2024 | News

TiumBio Initiates Phase 1b Trial for New Hemophilia Treatment TU7710

TiumBio Co., Ltd., a trailblazer in the biopharmaceutical landscape, dedicated to crafting groundbreaking therapies for rare and untreatabl...

 March 27, 2024 | News

Nanoscope Therapeutics Achieves Breakthrough in Retinitis Pigmentosa Treatment with MCO-010 Gene Therapy

Nanoscope Therapeutics, a pioneering biotechnology firm, unveiled groundbreaking results from the Phase 2b RESTORE trial of MCO-010...

 March 27, 2024 | News

Alphamab Oncology Launches Groundbreaking Clinical Trial in Australia for Advanced Cancer Treatment

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed in Australia in the clinical study (JSKN033-101) of JSKN0...

 March 26, 2024 | News

India Launches Pioneering Trials for MTBVAC TB Vaccine by Biofabri and Bharat Biotech to Revolutionize Global TB Prevention

Innovative Tuberculosis Vaccine, MTBVAC, Enters Clinical Trials in India In a major leap forward in the fight against tuberculosis (TB)—a deadly inf...

 March 24, 2024 | News

Vertex Pharmaceuticals Receives FDA Clearance for Innovative ADPKD Drug Trial

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) f...

 March 22, 2024 | News

Oscotec Inc. Gains FDA Orphan Drug Designation for Promising ITP Treatment Cevidoplenib

Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immun...

 March 22, 2024 | News

New Phase 3 Trial Begins for Potential Tuberculosis Vaccine M72/AS01E

The Bill & Melinda Gates Medical Research Institute (Gates MRI) has initiated a large-scale Phase 3 trial to evaluate the effic...

 March 20, 2024 | News

Singapore Approves Everest Medicines' NEFEGAN® for Adult Primary IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commerc...

 March 20, 2024 | News

Chipscreen Biosciences Announces Successful Phase II Trial of Chiglitazar for NASH Treatment

    The CGZ203 study, a randomized, double-blind, placebo-controlled trial conducted across 24 national clinical sites, aimed to assess the saf...

 March 19, 2024 | News

BeiGene's TEVIMBRA Wins FDA Nod for Advanced Esophageal Cancer Post-Chemotherapy

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has app...

 March 15, 2024 | News

Almirall and Eloxx Pharmaceuticals Forge Exclusive Global License Agreement for Rare Disease Treatment ZKN-013

Almirall, S.A. (BME:ALM), a global biopharmaceutical company, and Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a clinical-stage biopharmaceutical innovator, ha...

 March 14, 2024 | News

Sanyou Biopharmaceuticals Launches Groundbreaking Intelligent Innovative Biologics R&D Service Platform

Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," ...

 March 13, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close